Intelligent Bio Solutions Inc. (NASDAQ: INBS) has announced a significant expansion in the U.S. Forensic Use Only Market through its strategic partnership with SMARTOX, a Texas-based leader in drug and alcohol screening services. This collaboration has resulted in the deployment of over 50 INBS Intelligent Fingerprinting Drug Screening Readers and the conduction of more than 7,000 tests, including over 1,500 in 2024 alone. This surge in usage underscores the growing demand for INBS's innovative, rapid, and non-invasive drug testing solution.
The technology developed by INBS offers an alternative to traditional urine and saliva tests by utilizing fingerprint sweat analysis. This method enhances efficiency while improving the dignity and ease of use for individuals undergoing testing in corrections, rehabilitation, and drug court environments. The company is making strides toward obtaining FDA clearance for its codeine opiate test, with ambitions to extend its reach into workplace drug testing later this year. More information about the company's technology can be found at https://www.intelligentbiosolutions.com.
Intelligent Bio Solutions Inc. provides intelligent, rapid, non-invasive testing solutions through its Intelligent Fingerprinting Drug Screening System. The system transforms portable testing with fingerprint sweat analysis, which holds promise for broader applications beyond current forensic uses. Designed to be hygienic and cost-effective, the system screens for recent use of commonly abused drugs in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With the ability to collect samples in seconds and deliver results in under ten minutes, this technology represents a significant advancement for employers in safety-critical industries.
The partnership with SMARTOX highlights the effectiveness and reliability of INBS's technology while marking a pivotal step in the company's expansion within the U.S. forensic market. As INBS continues to innovate and seek regulatory approvals, its solutions are expected to play a crucial role in addressing drug testing challenges across various sectors, offering a faster, more dignified, and efficient alternative to traditional methods. The growing adoption of this technology through partnerships like the one with SMARTOX demonstrates the market's recognition of the advantages of non-invasive testing approaches.
